Year: 2020
Type: article
Abstract: Atherosclerosis is the leading cause of cardiovascular disease (CVD). Immune cells and their mediators drive the chronic arterial inflammation that is a hallmark of atherosclerosis, with the addition of excessive lipid markers [1]. Despite inflammation being the major contributor to the development of atherosclerosis, the mainstay of treatments and prevention strategies focus predominantly on lowering blood pressure, cholesterol levels, and platelet counts. Recently, the importance of targeting inflammation was highlighted by the CANTOS trial, which demonstrated that targeting IL-1β proved therapeutically beneficial in reducing recurrence of cardiac events, independent of cholesterol levels [2].
Source: EBioMedicine
Authors: Shuang Chen, Timothy R. Crother
Institution: Cedars-Sinai Medical Center
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,500
OpenAlex ID: W3022564541